Wilmington Based Biotech Company Incyte Joins the S&P 500

Incyte Corp. has joined the prestigious Standard & Poor’s 500, an index of the 500 most widely held stocks on the New York Stock Exchange and Nasdaq.

“The [S&P 500] index is an important threshold for us because it has put us into a bigger arena of life sciences companies,” said Dave Gryska, Incyte’s chief financial officer.

In the past year, Incyte’s stock has skyrocketed, nearly doubling from $75 a share to today’s high of $133.

Incyte has one drug which has been approved by the U.S. Food and Drug Administration (FDA), Jakafi. Which treats a rare blood cancers. Incyte stated that it expects Jakafi to generate $1 billion in sales in 2017.

Gryska added that, “Being added to the S&P 500 listing will help Incyte attract talent to Delaware in the highly competitive life sciences market.”

Read the full article at DelawareOnline.com 

Stay Up-to-Date on Business News in Wilmington

Sign up for Our Monthly Newsletter!

Incyte logo from (PRNewsFoto/Incyte Corporation)

  • Show Comments

Your email address will not be published. Required fields are marked *

comment *

  • name *

  • email *

  • website *

Ads

You May Also Like

SmallBiz Spotlight: Why Fly Internet

Tired of two bad options when it comes to internet service? Mike Palita and Mark Thompson decided to ...

Mayor Presenting Police Chief, Incoming DCAD President at June 27 Event

WHAT: Wilmington Mayor Mike Purzycki and Downtown Visions executive director Martin Hageman will host a Downtown Wilmington Meet-and-Greet featuring ...

MAYOR TO LAUD DONATION OF 450 ART KITS TO KIDS IN NEED 2/6

ADVISORY: Mayor, Jefferson Awards Foundation to celebrate donation of art kits to help local children ...

Copyright © 2019 WilmToday.com
Designed and Developed in Partnership with
Tapp Network - Mission-driven Marketing & Technology
Located in Wilmington, DE